Compass Total Assets from 2010 to 2024

CMPX Stock

USD 1.50 0.01 0.67%

Compass Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 120.5 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2018-06-30

Previous Quarter

161.1 M

Current Value

155.6 M

Quarterly Volatility

73.1 M

Covid

Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 8.3 M or Interest Income of 8.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.4. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.

Check out the analysis of Compass Therapeutics Correlation against competitors.

For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Latest Compass Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Compass Therapeutics over the last few years. Total assets refers to the total amount of Compass Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Compass Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Compass Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 156.88 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Compass Total Assets Regression Statistics

	Arithmetic Mean	86,311,971
	Geometric Mean	76,501,492
	Coefficient Of Variation	55.46
	Mean Deviation	38,068,624
	Median	64,625,000
	Standard Deviation	47,872,454
	Sample Variance	2291.8T
	Range	169.3M
	R-Value	0.62
	Mean Square Error	1507.9T
	R-Squared	0.39
	Significance	0.01
	Slope	6,676,864
	Total Sum of Squares	32084.8T

Compass Total Assets History

	2024	120.5 M
	2023	156.9 M
	2022	199.6 M
	2021	153.8 M
	2020	51.9 M
	2019	30.4 M

Other Fundumenentals of Compass Therapeutics

Intangibles To Total Assets

Compass Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Long Term Debt Total	Capital Surpluse	Net Receivables
Total Assets		0.9	0.87	0.58	-0.27	-0.85	0.67	-0.75	-0.76	0.9	0.71	1.0	-0.79	1.0	-0.83	-0.79	-0.43	-0.37	0.93	-0.37
Total Stockholder Equity	0.9		0.99	0.75	-0.21	-0.96	0.53	-0.95	-0.96	1.0	0.87	0.91	-0.96	0.9	-0.64	-0.96	-0.67	-0.57	0.91	-0.57
Net Tangible Assets	0.87	0.99		0.73	-0.14	-0.98	0.57	-0.94	-0.95	0.99	0.86	0.88	-0.94	0.88	-0.65	-0.94	-0.71	-0.67	0.93	-0.67
Current Deferred Revenue	0.58	0.75	0.73		-0.05	-0.79	0.22	-0.87	-0.83	0.75	0.96	0.59	-0.72	0.59	-0.18	-0.72	-0.7	-0.3	0.71	-0.3
Net Debt	-0.27	-0.21	-0.14	-0.05		0.05	0.34	0.16	0.19	-0.21	-0.12	-0.26	0.25	-0.27	0.3	0.25	-0.5	-0.27	-0.09	-0.27
Retained Earnings	-0.85	-0.96	-0.98	-0.79	0.05		-0.58	0.92	0.92	-0.96	-0.88	-0.86	0.88	-0.86	0.65	0.88	0.73	0.7	-0.95	0.7
Accounts Payable	0.67	0.53	0.57	0.22	0.34	-0.58		-0.36	-0.39	0.53	0.38	0.68	-0.44	0.69	-0.6	-0.44	-0.5	-0.42	0.73	-0.42
Long Term Debt	-0.75	-0.95	-0.94	-0.87	0.16	0.92	-0.36		0.99	-0.95	-0.95	-0.76	0.96	-0.75	0.39	0.96	0.76	0.53	-0.82	0.53
Total Liab	-0.76	-0.96	-0.95	-0.83	0.19	0.92	-0.39	0.99		-0.96	-0.93	-0.77	0.98	-0.77	0.42	0.98	0.75	0.54	-0.82	0.54
Net Invested Capital	0.9	1.0	0.99	0.75	-0.21	-0.96	0.53	-0.95	-0.96		0.87	0.91	-0.96	0.9	-0.63	-0.96	-0.68	-0.57	0.91	-0.57
Short Long Term Debt	0.71	0.87	0.86	0.96	-0.12	-0.88	0.38	-0.95	-0.93	0.87		0.72	-0.87	0.72	-0.31	-0.87	-0.74	-0.39	0.82	-0.39
Total Current Assets	1.0	0.91	0.88	0.59	-0.26	-0.86	0.68	-0.76	-0.77	0.91	0.72		-0.8	1.0	-0.82	-0.8	-0.46	-0.38	0.94	-0.38
Capital Stock	-0.79	-0.96	-0.94	-0.72	0.25	0.88	-0.44	0.96	0.98	-0.96	-0.87	-0.8		-0.8	0.46	1.0	0.69	0.51	-0.8	0.51
Net Working Capital	1.0	0.9	0.88	0.59	-0.27	-0.86	0.69	-0.75	-0.77	0.9	0.72	1.0	-0.8		-0.83	-0.8	-0.45	-0.38	0.94	-0.38
Short Term Debt	-0.83	-0.64	-0.65	-0.18	0.3	0.65	-0.6	0.39	0.42	-0.63	-0.31	-0.82	0.46	-0.83		0.46	0.07	0.48	-0.77	0.48
Common Stock	-0.79	-0.96	-0.94	-0.72	0.25	0.88	-0.44	0.96	0.98	-0.96	-0.87	-0.8	1.0	-0.8	0.46		0.69	0.51	-0.8	0.51
Property Plant Equipment	-0.43	-0.67	-0.71	-0.7	-0.5	0.73	-0.5	0.76	0.75	-0.68	-0.74	-0.46	0.69	-0.45	0.07	0.69		0.59	-0.6	0.59
Long Term Debt Total	-0.37	-0.57	-0.67	-0.3	-0.27	0.7	-0.42	0.53	0.54	-0.57	-0.39	-0.38	0.51	-0.38	0.48	0.51	0.59		-0.56	1.0
Capital Surpluse	0.93	0.91	0.93	0.71	-0.09	-0.95	0.73	-0.82	-0.82	0.91	0.82	0.94	-0.8	0.94	-0.77	-0.8	-0.6	-0.56		-0.56
Net Receivables	-0.37	-0.57	-0.67	-0.3	-0.27	0.7	-0.42	0.53	0.54	-0.57	-0.39	-0.38	0.51	-0.38	0.48	0.51	0.59	1.0	-0.56

Click cells to compare fundamentals

About Compass Therapeutics Financial Statements

Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	156.9 M	120.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC